Karyopharm Therapeutics INC ( (KPTI) ) has released its Q2 earnings. Here is a breakdown of the information Karyopharm Therapeutics INC presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company focused on developing innovative cancer therapies, particularly through its pioneering work in nuclear export inhibition. In its latest earnings report for the second quarter of 2025, Karyopharm reported total revenue of $37.9 million, with U.S. net product revenue for its lead drug, XPOVIO, reaching $29.7 million, marking a 6% increase from the previous year. The company is on the brink of completing patient enrollment for its Phase 3 SENTRY trial in myelofibrosis, with top-line results expected in March 2026.
Key financial highlights include a reaffirmation of the full-year 2025 total revenue guidance between $140 million and $155 million, with U.S. XPOVIO net product revenue expected to range from $110 million to $120 million. The company is also exploring financing transactions and strategic alternatives to extend its cash runway and maximize value. Despite a net loss of $37.3 million for the quarter, Karyopharm continues to focus on expanding global patient access and advancing its clinical development programs.
The company reported a decrease in research and development expenses to $32.8 million and selling, general, and administrative expenses to $28.5 million, reflecting cost reduction efforts. However, the net loss was impacted by increased interest expenses and a decline in license and other revenue. Karyopharm’s cash position stood at $52.0 million as of June 30, 2025, down from $109.1 million at the end of 2024.
Looking ahead, Karyopharm remains committed to advancing its clinical trials across various cancer indications, including multiple myeloma and endometrial cancer, with several key data readouts anticipated in 2026. The company’s management is optimistic about the potential of selinexor to redefine treatment standards in myelofibrosis and other high unmet need cancer indications, pending positive trial outcomes.